spacer
home > > spring 2002 > drug information association's 14th annual euromeeting - basel, switzerland, 5th-8th march 2002
PUBLICATIONS


Drug Information Association's 14th Annual EuroMeeting - Basel, Switzerland, 5th-8th March 2002

The 14th annual DIA EuroMeeting is based on the premise that in the 21st Century only a relatively small proportion of all diseases can be adequately treated, nevermind cured. At a fundamental level there is a lack of understanding of the mechanism of disease - particularly the genetic basis of disease and its implications for rational drug treatment.

Of equal concern is that only a small proportion of all patients have access to safe medicinal products at affordable prices. The availability of safe and effective medicines is a real issue in third world countries where for many patients the cost of diagnosis and treatment are beyond their means. This leads to counterfeit and often dangerous substitutes being sold in those countries. Where treatments are available there is often a lack of clear information on the products and their rational use.

Regulatory authorities, government health departments and medical insurance companies add their own particular and specific hurdles to the early availability of effective treatments.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Richard Barrett of Pfizer Global Research and Development, UK

Richard Barrett of Pfizer Global Research and Development, UK is the Co-Chairperson of the Euro2002 Programme Committee, along with Manuel Zahn, of AstraZeneca, Sweden.
spacer
Richard Barrett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement